Recce Pharmaceuticals Ltd Overview
Recce Pharmaceuticals is a clinical-stage Australian biotechnology company developing a new class of synthetic polymer anti-infectives aimed at antimicrobial resistance (AMR). Its lead asset, RECCE® 327 (R327), is a broad-spectrum agent active against Gram-positive and Gram-negative bacteria, including resistant "superbug" strains. It is being developed as a topical gel (R327G), an intravenous infusion, and a nebulised inhaled therapy. R327 holds FDA Qualified Infectious Disease Product (QIDP) status with Fast Track designation and appears in the WHO antibacterial clinical pipeline. The near-term thesis rests on R327G in diabetic foot infections (DFI): a registrational, placebo-controlled Phase 3 in Indonesia (up to 310 patients, interim analysis at 155) and a pivotal active-comparator Phase 3 in Australia run to TGA and FDA standards. Recce has no product revenue, owns its manufacturing, and relies heavily on the Australian R&D Tax Incentive, US defence grants, an Avenue Capital debt facility and frequent equity raisings. Governance tensions with shareholders became acute in 2025–26.
Company's own description (FY26 Annual Report, paraphrased)
Recce describes itself as developing a new class of synthetic anti-infectives to tackle antibiotic-resistant superbugs. The pipeline consists of three patented, broad-spectrum synthetic polymer anti-infectives:
RECCE® 327 (R327): intravenous and topical therapy for serious and potentially life-threatening Gram-positive and Gram-negative infections, including resistant forms.
RECCE® 435 (R435): orally administered therapy for bacterial infections.
RECCE® 529 (R529): for viral infections.
The company attributes the platform's potential to overcome resistance to its "multi-layered mechanisms of action." It highlights that the WHO lists R327, R435 and R529 among antibacterial products in clinical development for priority pathogens, and that the FDA has granted R327 QIDP status under the GAIN Act with Fast Track designation. It also notes R327's inclusion in The Pew Charitable Trusts' antibiotic pipeline as the sole synthetic polymer and sepsis candidate, and that Recce wholly owns its automated manufacturing. In the Directors' Report, the principal activity is described as developing and commercialising new classes of synthetic anti-infectives against resistant superbugs and emerging viral pathogens.
Business model and revenue model
| Dimension | Current state (FY2026) | Planned / target state |
|---|---|---|
| Revenue from ordinary activities | Nil (FY2026 and FY2025) | First product revenue targeted after Indonesian approval of R327G (company guidance: approval anticipated in CY2026) |
| Product vs service vs licensing mix | 100% pre-revenue. "Other income" consists of the R&D tax incentive, grants and interest. | Hybrid: (a) direct or partner-led product sales in Indonesia and ASEAN; (b) out-licensing with Recce as manufacturer and supplier (MENA term sheet: upfront/milestones up to US$3.5m, plus a 30% royalty on net selling price and an additional 6% on annual net sales above US$50m) |
| Non-dilutive funding | R&D Tax Incentive (A$8.88m recognised in FY26); US defence grant income (A$0.50m in FY26); Canadian SR&ED refund (A$0.27m in FY25) | Advanced Overseas Finding of up to A$85m in eligible offshore R&D, eligible for the 43.5% refundable offset over three years |
| Debt funding | Avenue Venture Opportunity Fund II facility: A$30.55m total, A$11.49m drawn at 30 June 2026 | Remaining tranches subject to drawdown conditions |
| Equity funding | Placements, SPPs and entitlement offers; Acuity Capital at-the-market facility (to 31 January 2031) | Ongoing |
Value-chain position
Recce is vertically integrated across discovery (its in-house chemistry platform and an Anti-Infective Research Unit at the Murdoch Children's Research Institute in Melbourne), clinical development, and API and finished-product manufacturing (Macquarie Park, Sydney). Commercial distribution is expected to be partnered: PT Etana Biotechnologies is the Indonesian sponsor, and an unnamed Middle Eastern licensee is proposed under a non-binding term sheet. Under that term sheet, Recce would stay the manufacturer and supplier, giving it a manufacturing margin plus royalty. MST Access (February 2026) models a 92% gross margin at launch.
Customer types and end-markets (prospective)
| End-market | Customer type | Asset | Stage |
|---|---|---|---|
| Diabetic foot infections (mild to moderate) | Hospitals, wound-care clinics, podiatry, primary care; government payers (Indonesia, KSA/GCC); licensee distributors | R327G topical gel | Phase 3 (Indonesia, Australia) |
| ABSSSI / acute wound infections | Hospitals, emergency departments | R327G | Phase II completed (Feb 2025); folded into the DFI Phase 3 strategy |
| Burn wound infections (military and civilian) | US Department of War (formerly DoD) and US Army; burn centres | R327G | Preclinical (two CRADAs, US$2m CDMRP grant) |
| Complicated UTI / urosepsis / sepsis | Hospitals (IV) | R327 IV | Phase I and Phase I/II completed; Phase II planned |
| HAP/VAP (inhaled) | ICU and ventilated patients | Nebulised R327 | Preclinical (MCRI) |
| Biodefence countermeasures | US government | R327 | In-vitro data (MHSRS 2025) |
| Viral infections | — | R529 | Early research |
| Oral antibacterial | — | R435 | Early research |
Independent characterisation
Recce is a single-platform, single-lead-asset, pre-revenue biotech. Its valuation hinges on one binary event: positive Indonesian Phase 3 interim data for R327G, followed by Badan POM approval under expedited review. The platform is genuinely differentiated as a synthetic polymer anti-infective, which most AMR pipelines do not offer, and it carries meaningful external validation (QIDP/Fast Track, WHO and Pew listings, US Army CRADAs). Its clinical evidence, however, rests on open-label Phase II data in 30 patients and first-in-human safety data. Strategically, the company has pivoted from a US/IV-first sepsis story to an emerging-market, topical-first DFI story. That is cheaper and faster, but it targets lower-priced markets where its mechanism claims have not yet been tested in a controlled efficacy setting. The balance sheet is thin: A$2.7m cash and negative equity of about A$16.7m at 30 June 2026. Governance is the most visible non-clinical risk. The founder's family occupies the CEO and CSO roles, the chair is executive, the Board lacks an independent majority, and shareholders have repeatedly voted down remuneration and capital resolutions.
Strategy
Stated strategic themes (FY26 Annual Report, paraphrased; short quotes only)
-
Late-stage clinical execution: run two registrational Phase 3 DFI trials in parallel, deliver the Indonesian interim readout, and obtain Indonesian approval as the first commercial milestone.
-
Dual-market regulatory strategy: use the Australian pivotal trial, run to TGA and FDA standards, to support TGA and FDA submissions. AUS/US registration is targeted for 2028, with an FDA IND first.
-
Partnership-led international expansion: the Chairman frames MENA as part of "capital-efficient, partnership-led market expansion," using the clinical package and designations to license to regional operators.
-
US Government as a "second pillar": expand the Department of War burn wound programme through the CDMRP grant and the USAMRIID and USAISR CRADAs.
-
Pipeline breadth through preclinical research: inhaled R327 (HAP/VAP), IV R327 (UTI/urosepsis), and biodefence.
-
Non-dilutive funding first: R&D Tax Incentive, the A$85m Advanced Overseas Finding, grants and the Avenue debt facility, supplemented by equity.
-
Scientific credibility: the AR anticipates a peer-reviewed mechanism-of-action paper in CY2026. The September 2026 GM deck lists it as "published".
Strategic initiatives in the last 24 months
| Date | Initiative | Type | Detail / target |
|---|---|---|---|
| Jul 2024 | US DoD CDMRP grant | Government funding | US$2m for R327G in burn wounds |
| Dec 2024 | Indonesian Phase 3 approval | Clinical / regulatory | Expedited review; first DFI trial of its kind in Indonesia |
| Apr 2025 | USAMRIID CRADA | Partnership | DTRA-funded |
| Jun 2025 | Avenue debt facility | Financing | Up to US$20m; warrants equal to 8% of the loan amount |
| Sep 2025 | Indonesian Phase 3 dosing | Clinical | 5 sites; up to 310 patients |
| Dec 2025 | Advanced Overseas Finding | Funding | Up to A$85m of offshore R&D eligible for the 43.5% offset over 3 years |
| Feb 2026 | USAISR CRADA | Partnership | Walker-Mason burn model |
| May 2026 | MENA licence term sheet | Commercial | 10-year exclusive; 12 countries |
| Jun 2026 | Australian trial elevated to pivotal Phase 3 | Clinical | Active comparator; mild and moderate DFI; ulcers below the knee |
| Jun–Jul 2026 | Placement and SPP | Financing | A$6.4m. Planned use: A$3.2m balance sheet and licensing, A$2.0m trials, A$2.0m IND-enabling work (FDA, BPOM), A$0.8m working capital and costs |
| Aug 2026 | HREC approval of comparator study | Clinical | Pivotal Phase 3 DFI |
Sustainability / ESG commitments: none disclosed beyond policies. Cost programmes: none announced; the FY26 cost reduction was implicit.
Guidance and targets (latest disclosures)
| Item | Guidance | Source | Track record |
|---|---|---|---|
| Indonesian interim data | Q3 CY2026 (GM deck, Sep 2026) | GM presentation | Earlier guidance: Q1 2026 (Biotech Dispatch, Sep 2025; MST Access, Feb 2026). Results "by late 2025" was guided at trial approval in Dec 2024. Repeated slippage; no readout found as of 14 Oct 2026. |
| Indonesian approval / launch | Approval anticipated CY2026; commercialisation 2027 | Q4 FY26 4C; GM deck | Jan 2026 presentation targeted availability in Indonesia in 2026; Edison assumed launch in H2 CY2026 |
| MENA definitive agreement | "Next quarter" / Q4 CY2026 | Q4 FY26 4C (internally inconsistent wording) | Pending |
| KSA commercial approval | Targeted "by year end" with expedited review, relying on Indonesian data | Q4 FY26 4C | Contingent on Indonesian data |
| Australian Phase 3 | Full enrolment by end of 2027 | Q4 FY26 4C | 18 of about 200 patients treated at 21 Jul 2026 |
| AUS/US registration | 2,028 | FY26 AR | — |
| FDA IND for R327G | Planned; MST Access expected H1 CY2026 | FY26 AR; MST | Not yet announced |
| Medium-term financial targets | None published | — | — |
Products & Services
No product is approved or marketed. The catalogue below lists every disclosed development product and formulation.
RECCE® 327 Topical Gel (R327G) — flagship
| Attribute | Detail |
|---|---|
| Description | Topical gel of R327, a synthetic polymer anti-infective with broad-spectrum activity, designed as a next-generation gel wound dressing |
| Key capabilities | Phase II ABSSSI (Australia, 30 patients, open label): 93% primary efficacy endpoint over 14 days and 86% clinical response by day 7, with no serious adverse events (FY25 and FY26 ARs). Preclinical burn models: about 3-log reduction of P. aeruginosa by day 4 and 4-log by day 8; about 2-log reduction of MRSA by day 4 and 3-log by day 8. It outperformed Soframycin with once-daily versus twice-daily dosing and accelerated wound contraction (FY26 AR). |
| Indications | DFI (mild and moderate, about 80% of DFI presentations per company); ABSSSI; burn wound infections |
| Target customer | Hospital and community wound care; government health systems; military field kits |
| Development status | Indonesian Phase 3: registrational, double-blind, placebo-controlled, 5 sites, up to 310 patients, interim analysis at 155, primary endpoint Lipsky Scale clinical response. Australian Phase 3: pivotal, active-comparator (one of four physician-selected antibiotics), non-inferiority and superiority design, about 200 patients (Q4 FY26 4C; the GM deck says 208), interim at 50%. |
| Launch timing (guidance) | Indonesia approval anticipated in CY2026 (Q4 FY26 4C; FY26 AR). The September 2026 GM deck points to commercialisation in 2027. Australia/US registration targeted for 2028 (FY26 AR). |
| Pricing | MENA term sheet proposes US$1,500 per treatment, subject to Saudi regulatory agreement (Q4 FY26 4C). Indonesian pricing not publicly disclosed. |
| Regulatory designations | FDA QIDP and Fast Track (R327); expedited review status in Indonesia |
RECCE® 327 Intravenous (R327 IV)
| Attribute | Detail |
|---|---|
| Description | IV infusion for serious Gram-positive and Gram-negative infections, including urinary tract infections, urosepsis and sepsis |
| Key data | Phase I (R327-001, reported 20 Jul 2023): 80 healthy males in 8 cohorts, 50mg to 6,000mg one-hour infusion, no SAEs, linear PK, urine concentrations up to 21x plasma (FY26 AR says up to 20x). Phase I/II: 3,000mg over 30 minutes safe (Sep 2023). Edison notes a 4,000mg 30-minute cohort was cleared. Ex vivo, R327-treated urine eliminated E. coli. |
| Status | A Phase II UTI/urosepsis trial is planned. MST Access had expected a start in H1 CY2026; no start was confirmed in FY26 filings. |
| Commercial view | Edison sees the IV formulation as Recce's largest commercial opportunity (sepsis/urosepsis and cUTI). MST Access estimates about A$105m more is needed to bring the IV programmes to commercial readiness. |
| Pricing | — |
Inhaled / nebulised R327
| Attribute | Detail |
|---|---|
| Description | Nebulised R327 for hospital- and ventilator-acquired pneumonia |
| Key data | MCRI model with carbapenem-resistant Acinetobacter baumannii, 40 mice: nebulised R327 produced a 4-log (>99.99%) reduction in lung bacterial burden, approaching the limit of detection, with early signs of lower inflammation. The company notes meropenem cannot be effectively nebulised. |
| Status | Preclinical; the GM deck lists Phase I/II and registrational trials as future steps |
RECCE® 435 (R435)
Oral therapy for bacterial infections; listed on the WHO pipeline. Early-stage. Specifications, timelines and pricing are not publicly disclosed.
RECCE® 529 (R529)
Antiviral candidate; listed on the WHO pipeline. Early-stage. Specifications are not publicly disclosed.
Biodefence application of R327
At MHSRS 2025 (Kissimmee, Florida, 4–7 August 2025), Recce presented in-vitro activity against CDC Category A/B threat pathogens: B. anthracis, F. tularensis, B. mallei, B. pseudomallei and Y. pestis (FY26 AR). There is no clinical programme.
Services
Recce offers no commercial services.
Financial Narrative
Income statement
Sources: FY24–FY26 net loss, R&D incentive and EPS from company Annual Reports and Appendix 4E. FY22–FY25 other income, operating income, EBITDA and interest from StockAnalysis (aggregator), which labels other income as "revenue". FY26 other income of A$9,939,158 from the FY26 report via FilingReader. Total expenses are derived as net loss plus other income. FY22–FY23 EPS is aggregator data rounded to whole cents.
Margins and growth. Gross, operating, EBITDA and net margins are not meaningful with nil revenue, and revenue CAGR is undefined. Other income grew at a 34% CAGR from FY2022 to FY2026 (analyst-derived from 3.08 to 9.94), driven by the rising R&D Tax Incentive as clinical spend scaled.
Commentary. Losses widened every year from FY2022 to FY2025, peaking at A$21.4m as the Phase II ABSSSI trial ran, Phase 3 start-up began, financing costs rose and share-based payments increased. FY2026 is an inflection: the net loss fell 30% to A$14.96m. The company attributes this to lower R&D expenditure. The R&D incentive also rose to A$8.88m, helped by the Advanced Overseas Finding, which lets Indonesian trial spend qualify. Lower R&D spend during a Phase 3 year mainly reflects funding constraints: Q2 FY26 ended with only A$0.4m of cash, per MST Access. It does not signal operating efficiency. Loss per share fell from 9.04c to 5.17c, helped by a larger weighted share count after the FY25 raisings.
Data conflict. StockAnalysis reports a trailing-twelve-month loss to 31 December 2025 of A$30.25m. That figure is inconsistent with the audited H1 and FY26 results and appears to be an aggregator artefact, so it has been disregarded.
Balance sheet
Sources: FY22–FY25 from StockAnalysis (aggregator), cross-checked against Simply Wall St for FY25 (total debt A$10.13m, equity -A$3.05m, assets A$12.41m). FY26 cash of A$2,694,474 and NTA per share from the FY26 Annual Report. FY26 equity of about -A$16.7m and accumulated losses of about A$101m come from shareholder commentary at the 2 September 2026 GM (Mayne Report); this is consistent with NTA of -5.78c across about 289m shares. FY26 Avenue drawn balance from the Q4 FY26 Appendix 4C, Section 7. FY26 net debt is analyst-derived as A$11.49m drawn less A$2.69m cash and excludes leases. Goodwill and intangibles are nil because no capitalised intangibles were identified.
Data conflict. The Q4 FY26 Appendix 4C reports cash at 30 June 2026 of A$2,896,729, while the audited Annual Report gives A$2,694,474. The difference of about A$0.2m is unexplained in the material reviewed.
Commentary. Equity has been negative since FY2023 because accumulated losses outran capital raised and debt-like funding filled the gap: R&D advance loans in FY23–FY24, then the Avenue facility from June 2025. Working capital turned positive in FY2025 only because of the A$15.8m+ equity raise and the reclassification of debt to long-term. At 30 June 2026 the company held A$3.94m of placement proceeds as "equity pending allotment"; the shares were allotted on 1 July 2026.
Cash flow
Source: StockAnalysis (aggregator). Cross-check: FY25 cash of A$10.45m less A$7.75m gives A$2.70m, matching the audited FY26 cash of A$2.69m. The Q4 FY26 Appendix 4C gives FY26 net operating cash outflow of A$10.02m (aggregator: A$9.89m). The aggregator's FY25 equity issuance of A$28.35m exceeds the A$15.8m the company cites for FY25. The likely explanation is that the July–August 2024 A$8m placement and SPP also fell in FY25, but the variance is unreconciled.
FY2026 operating cash outflow by category (Q4 FY26 Appendix 4C, AUD)
Commentary. Cash burn roughly halved in FY2026, from A$20.4m to about A$10m. That came from both A$5.8m of tax incentive receipts and reduced trial spend. Q4 FY26 operating outflow was A$2.17m, and the company's Appendix 4C estimated 10.87 quarters of funding based on A$23.6m of "available funding", which includes A$20.7m of undrawn Avenue facility subject to conditions. On cash alone, runway at 30 June 2026 was about one quarter before the July 2026 inflows: the A$3.67m tax refund and the A$2.4m SPP.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Entity / Unit Details
| Entity / unit | Function | Disclosure status |
|---|---|---|
Recce Pharmaceuticals Ltd (parent) | Listed holding entity; R&D sponsor; IP owner | FY26 AR |
Controlled entities | The AR refers to "controlled entities" (the Group). Names were not captured in this research. | Not publicly disclosed in material reviewed |
Macquarie Park manufacturing | API and finished-product manufacture (GMP) | Company releases |
Anti-Infective Research Unit at MCRI (Melbourne) | Preclinical research (e.g., HAP/VAP models) | FY26 AR |
Outsourced finance function | CFO Justin Reynolds is a partner at Pitcher Partners Sydney (outsourced) | FY26 AR |
Outsourced company secretarial | Maggie Niewidok, Kardos Scanlan Corporate Lawyers | FY26 AR |
Results by Segment
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue – Anti-infectives R&D (AUD Mn) | 0 | 0 | 0 |
Segment net loss – Anti-infectives R&D (AUD Mn) | -17.66 | -21.43 | -14.96 |
Contribution to total revenue (%) | 0 | 0 | 0 |
Capital Programmes
| Programme | Contents | FY2026 status |
|---|---|---|
R327 Topical (R327G) | DFI Phase 3 (Indonesia, Australia); ABSSSI Phase II complete; burn wound (US) | Lead value driver |
R327 Intravenous | UTI/urosepsis, sepsis | Phase I and I/II complete; Phase II planned |
R327 Inhaled | HAP/VAP nebulised | Preclinical |
R435 | Oral antibacterial | Early research |
R529 | Antiviral | Early research |
Government / biodefence | US Department of War burn wound programme; bioterrorism pathogens | Preclinical / in vitro |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from ordinary activities (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Other income incl. R&D tax incentive, grants, interest (AUD Mn) | 3.08 | 4.37 | 5.03 | 7.51 | 9.94 |
of which R&D Tax Incentive recognised (AUD Mn) | — | — | 4.91 | 6.74 | 8.88 |
of which US defence grant income (AUD Mn) | — | — | — | — | 0.50 |
Total expenses, analyst-derived (AUD Mn) | 14.07 | 17.45 | 22.69 | 28.94 | 24.90 |
Gross profit (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Operating income, aggregator (AUD Mn) | -9.65 | -12.88 | -17.00 | -20.41 | — |
EBITDA, aggregator (AUD Mn) | -9.60 | -12.83 | -16.93 | -20.33 | — |
Interest expense, aggregator (AUD Mn) | 0.01 | 0.18 | 0.84 | 1.21 | — |
Pre-tax income (AUD Mn) | -10.99 | -13.08 | -17.66 | -21.43 | -14.96 |
Net income (AUD Mn) | -10.99 | -13.08 | -17.66 | -21.43 | -14.96 |
EPS basic and diluted (AUD cents) | -6 | -8 | -9.97 | -9.04 | -5.17 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents (AUD Mn) | 11.58 | 1.56 | 4.42 | 10.45 | 2.69 |
Total current assets (AUD Mn) | 12.18 | 1.95 | 5.14 | 11.39 | — |
PP&E (AUD Mn) | 0.44 | 0.61 | 1.23 | 1.03 | — |
Total assets (AUD Mn) | 12.62 | 2.56 | 6.37 | 12.41 | — |
Current liabilities (AUD Mn) | 2.45 | 4.85 | 15.07 | 6.13 | — |
Total debt incl. leases (AUD Mn) | 0.07 | 3.30 | 10.50 | 10.77 | — |
Short-term debt (AUD Mn) | 0 | 3.05 | 9.69 | 1.53 | — |
Long-term debt (AUD Mn) | 0 | 0 | 0 | 8.60 | — |
Avenue loan facility drawn (AUD Mn) | — | — | — | — | 11.49 |
Net debt, analyst-derived (AUD Mn) | -11.51 | 1.74 | 6.08 | 0.32 | 8.80 |
Total liabilities (AUD Mn) | 2.56 | 5.14 | 15.89 | 15.47 | — |
Shareholders' equity (AUD Mn) | 10.06 | -2.59 | -9.52 | -3.05 | -16.7 |
Goodwill and intangibles (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Working capital (AUD Mn) | 9.74 | -2.90 | -9.93 | 5.26 | — |
NTA per share (AUD cents) | — | — | — | -1.06 | -5.78 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -9.01 | -12.69 | -13.01 | -20.44 | -9.89 |
Capital expenditure (AUD Mn) | -0.04 | -0.04 | -0.14 | -0.03 | -0.06 |
Free cash flow (AUD Mn) | -9.05 | -12.73 | -13.15 | -20.47 | -9.95 |
Equity issued (AUD Mn) | 0.29 | 0.10 | 11.15 | 28.35 | 3.94 |
Debt issued (AUD Mn) | 0 | 2.88 | 10.09 | 12.22 | 0.06 |
Debt repaid (AUD Mn) | -0.14 | -0.17 | -4.51 | -11.92 | -1.71 |
Financing cash flow (AUD Mn) | -0.24 | 2.71 | 16.17 | 26.92 | 2.01 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (AUD Mn) | -9.29 | -10.02 | 2.85 | 6.03 | -7.75 |
Financial Analysis
| Category | Year to date FY2026 |
|---|---|
Research and development | -11,659,449 |
Staff costs | -2,780,924 |
Administration and corporate | -1,400,334 |
Advertising and marketing | -483,320 |
Government grants and tax incentives received | 5,807,722 |
Net operating cash flow | -10,024,008 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROA (%) | -87 | -511 | -277 | -173 |
Current ratio (x) | 4.97 | 0.40 | 0.34 | 1.86 |
Debt to equity (x) | 0.01 | -1.27 | -1.10 | -3.53 |
Ratio | Assessment | — | — | — |
ROE | Not meaningful; equity negative from FY2023 | — | — | — |
ROIC | Not meaningful; negative invested capital and operating losses | — | — | — |
Net debt / EBITDA | Not meaningful; EBITDA negative | — | — | — |
Interest coverage | Not meaningful; operating losses. Aggregator FY25 interest expense was A$1.21m. | — | — | — |
Asset turnover | Zero; no revenue | — | — | — |
Cash conversion cycle | Not applicable; no trade receivables or inventory cycle | — | — | — |
Results by Region
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Revenue – Australia (AUD Mn) | 0 | 0 | 0 |
Revenue – Asia ex-Australia (AUD Mn) | 0 | 0 | 0 |
Revenue – Americas (AUD Mn) | 0 | 0 | 0 |
Revenue – EMEA (AUD Mn) | 0 | 0 | 0 |
Other income – Australia, R&D Tax Incentive (AUD Mn) | 4.91 | 6.74 | 8.88 |
Other income – USA, defence grant (AUD Mn) | — | — | 0.50 |
Other income – Canada, SR&ED refund (AUD Mn) | — | 0.27 | — |
Region Overview
| Region | Role | Status |
|---|---|---|
Indonesia | First commercial market; registrational Phase 3 | Approval anticipated CY2026 |
ASEAN (Malaysia, Thailand, Singapore, Philippines) | Follow-on approvals; company cites about a US$1.5bn opportunity | Post-Indonesia |
MENA (12 countries per AR; the 4C names KSA, UAE, Kuwait, Oman, Bahrain, Qatar, Egypt, Algeria, Morocco) | Out-licensed distribution | Non-binding term sheet; definitive agreement guided for "next quarter" / Q4 CY2026 |
Australia | Pivotal Phase 3; TGA filing | Registration targeted 2028 |
United States | FDA IND, then NDA; DoD/Department of War burn programme | IND planned; registration targeted 2028 |
Brazil, China, Japan, Canada, Israel, Hong Kong, Vietnam | Patent coverage | No development activity disclosed |
Share Price History
| Date | Price (AUD) | Source |
|---|---|---|
Jan 2016 (IPO) | 0.20 | Biotech Daily |
9 Oct 2020 (option grant date) | 1.115 | FY26 AR |
30 Jun 2025 | 0.29 | Market Index |
10 Feb 2026 | 0.58 | MST Access |
4 Apr 2026 | 0.47 | Edison |
24 Jul 2026 | 0.36 | StockAnalysis |
1 Sep 2026 | 0.36 | InvestSMART |
22 Sep 2026 | 0.325 | StockAnalysis |
29 Sep 2026 | 0.32 | Google Finance |
Metric | FY2025 | FY2026 |
Fiscal year-end share price (AUD) | 0.29 | — |
Performance metric | Value | Source |
52-week range | A$0.31 – A$0.73 | Google Finance (29 Sep 2026) |
5-year high | A$1.38 | MarketScreener |
10-year high | A$1.88 | MarketScreener |
1-year relative performance | -22.6% vs sector; -35.0% vs ASX 200 | Market Index |
Absolute 1-, 3- and 5-year total return | Price data points imply a steep 5-year decline from above A$1.00 in late 2020 to A$0.32. | — |
Beta (5-year) | 0.39 | StockAnalysis |
Valuation Multiples
| Multiple | Recce | Comment |
|---|---|---|
Market cap | About A$99.4m | Google Finance |
Enterprise value | About A$108m (A$99.4m plus about A$8.8m net debt at 30 Jun 2026) | Analyst-derived; StockAnalysis gave EV of A$108.25m on 24 Jul 2026 |
P/E | n.m. (loss-making); MarketScreener consensus P/E of -6.8x for 2026 | Aggregator |
EV/Sales | n.m. (nil revenue); aggregator quotes are based on other income | — |
P/B | Negative (equity about -A$16.7m) | — |
Firm Details
| Firm | Type | View |
|---|---|---|
MST Access | Company-sponsored | A$764m valuation, A$2.40 per share (A$2.17 fully diluted); rNPV at a 12.5% discount rate; 10 Feb 2026 |
Edison Investment Research | Company-sponsored | rNPV at a 12.5% discount rate across four programmes; per-share value not captured in this research |
Consensus | Simply Wall St reports 2 analysts contributing estimates | Consensus targets not publicly disclosed |
Capital Markets
| Item | Status |
|---|---|
Dividend history and policy | No dividend has ever been paid or declared (FY26 Appendix 4E) |
Buybacks | None authorised |
Credit ratings (Moody's, S&P, Fitch) | None; unrated |
Debt maturity profile | Avenue facility: A$30.55m total, A$11.49m drawn at 30 Jun 2026. Interest rate and amortisation schedule not captured in this research. Warrants exercisable for 5 years from execution. Aggregator FY25 split: A$1.53m current and A$8.60m non-current. |
Equity overhang | Avenue warrant (up to 4.63m shares); Acuity ATM (about 4.5m shares); unlisted options; MST counted 32.9m options and performance rights in Feb 2026 |
Capital raised FY2025–FY2026 | A$22.2m of equity in total (A$15.8m in FY25 plus A$6.4m in FY26, per the CEO letter) |
Analyst Conclusions
Management guidance (latest)
-
Indonesian Phase 3 interim readout guided for Q3 CY2026; no readout had been found as of 14 October 2026, so the guidance window has passed.
-
Indonesian regulatory approval anticipated in CY2026, with commercialisation in 2027.
-
Definitive MENA licence agreement guided for Q4 CY2026; KSA approval targeted to rely on Indonesian data.
-
Australian pivotal Phase 3 fully enrolled by end-2027; AUS/US registration targeted for 2028.
-
An FDA IND, a Phase II IV UTI/urosepsis trial, and a peer-reviewed mechanism-of-action publication are all planned.
-
No revenue or earnings guidance has been issued. No consensus revenue estimates were verified.
Bull case
-
Binary upside from a low base. At about A$99m market cap, positive interim data on the placebo-controlled Indonesian trial, with the protocol designed to show significance at about 155 patients, could trigger approval under expedited review, a definitive MENA deal and ASEAN filings. MST's sponsored A$2.40 per share valuation shows the theoretical gap.
-
Validated, differentiated platform. QIDP and Fast Track, the WHO and Pew listings, two US Army CRADAs and a clean Badan POM inspection all support the platform. One molecule spans topical, IV and inhaled markets, including Edison's preferred IV sepsis and cUTI franchise.
-
Non-dilutive leverage. The A$85m Advanced Overseas Finding makes Indonesian trial spend eligible for a 43.5% cash refund. The FY26 incentive of A$8.88m offset about 59% of the loss, and undrawn Avenue debt of A$20.7m could fund the path to launch if conditions are met.
Bear case
-
Credibility of timelines and evidence. The interim readout has slipped at least three times (late 2025, Q1 2026, Q3 2026). Efficacy evidence remains a 30-patient open-label Phase II, and topical DFI has a history of Phase 3 failure.
-
Balance-sheet fragility and dilution. Cash was A$2.69m and equity about -A$16.7m at 30 June 2026, and debt drawdowns are conditional. The SPP raised only 60% of its target, and shareholders blocked option sweeteners, constraining future capital-raising tools.
-
Governance overhang. Successive remuneration strikes, the 2 September 2026 defeat of all resolutions, and the s249N director nominations point to a possible board contest at the 2026 AGM. Family control of executive roles, related-party consulting and an executive chair compound the discount.
Key catalysts and monitorables (next 12 months)
| Catalyst | Expected timing | Why it matters |
|---|---|---|
| Indonesian Phase 3 interim analysis (155 patients) | Overdue against Q3 CY2026 guidance | The single most important value driver |
| 2026 AGM outcome, including s249N resolutions and board nominations | Q4 CY2026 (per 6 Oct 2026 notice) | Board composition, strategy continuity, capital access |
| Definitive MENA licence | Q4 CY2026 (guided) | First upfront cash and commercial validation |
| Badan POM marketing authorisation | CY2026 to 2027 | First revenue |
| Q1 FY27 Appendix 4C | Late Oct 2026 | Cash runway and drawn debt |
| FY2026 R&D Tax Incentive refund | H2 CY2026 to H1 CY2027 | Large non-dilutive inflow (A$8.88m recognised) |
| Avenue tranche drawdowns | Event-driven | Liquidity; covenant headroom |
| FDA IND submission | 2026–2027 | US pathway credibility |
| Australian Phase 3 enrolment pace | Ongoing (18 patients at Jul 2026) | Determines TGA/FDA timing |
| USAISR burn model results | 2026–2027 | US defence procurement potential |
Analyst verdict
Recce Pharmaceuticals is a high-risk, event-driven proposition whose investment case has narrowed to one question: will R327G show a statistically significant clinical response over placebo in Indonesian diabetic foot infections? Everything else depends on that answer, including MENA royalties, ASEAN expansion, the Saudi approval path and the credibility of the wider polymer platform. The scientific narrative is unusually rich for a company of about A$100m market capitalisation. A genuinely novel synthetic class, FDA QIDP and Fast Track status, WHO and Pew pipeline recognition, two US Army research agreements and a clean regulatory inspection add up to a substantive platform, not a story stock. The FY2026 numbers also show improved cost discipline: the net loss fell 30% to A$14.96m and operating cash burn halved to about A$10m, aided by an A$85m Advanced Overseas Finding that turns offshore trial spend into refundable tax credits.
Against that, the balance sheet is precarious and governance is a live, escalating risk. At 30 June 2026 the company held A$2.7m of cash against about A$11.5m of drawn venture debt and negative equity near A$16.7m, and it depends on conditional debt tranches and tax refunds. Shareholders have now rejected remuneration and capital resolutions at consecutive meetings and lodged s249N director nominations. Management's repeated slippage on the interim readout erodes the guidance credibility that a binary-event stock needs.
Verdict: speculative; event-driven. Risk-tolerant investors with a clear view on topical anti-infective efficacy may find the asymmetry attractive at about A$0.32 per share. Institutional capital should wait for three things: (1) the Indonesian interim readout with full statistics, (2) resolution of the 2026 AGM board contest, and (3) a definitive, funded MENA agreement. Until then, the dominant risks are dilution and governance rather than science.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Appointed | Independent | Education | Prior roles / other boards |
|---|---|---|---|---|---|
Dr John Prendergast | Executive Chairman (US-based) | 23 Apr 2018 | No | BSc (Hons), MSc and PhD (UNSW); CSS Admin & Mgmt (Harvard) | Co-founder and Chairman, Palatin Technologies (NYSE: PTN); Executive Chairman, Angis Bio; former Lead Director, Nighthawk Biosciences / Heat Biologics; co-founder of Avigen, AVAX, MediciNova; former MD, The Castle Group. Cited as responsible for three NDA approvals. |
James Graham | Managing Director and CEO | Director 23 Jun 2015; CEO 28 Aug 2020 | No | BCom (Entrepreneurship), GAICD | Marketing, business development and commercialisation background. Reported to be Dr Melrose's grandson (Biotech Daily; Business News Australia). |
Michele Dilizia | Executive Director and Chief Scientific Officer | 26 Jun 2015 | No | BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM | Co-inventor; medical scientist (microbiology and regulatory affairs); earlier career in PR and marketing. Reported to be Dr Melrose's daughter (Biotech Daily). |
Dr Justin Ward | Executive Director and Head of Chemistry / Principal Quality Chemist | 8 Jul 2019 | No | BSc (Chem), PhD (Chem), MPharm, MRACI, CChem | Pfizer (regulatory data); Laboratory Manager, Solbec; Quality Manager, Phebra |
Dr Alan Dunton | Non-Executive Director and Chief Medical Officer/Adviser (US-based) | 14 Jul 2020 | Yes (per company) | MD (NYU); BS Biochemistry (SUNY Buffalo) | President and MD, Janssen Research Foundation (J&J); CEO of Panacos and Metaphore; COO, Emisphere; boards of Palatin, Oragenics, CorMedix. Cited as responsible for about 20 NDA approvals. |
Alistair McKeough | Non-Executive Director | 1 Sep 2022 | Yes | BA, LLB, LLM | Solicitor; former Recce Company Secretary (from 2017); Automic Group leadership; director of Tissue Repair Ltd (ASX: TRP) |
Executive Leadership Team — Arthur Kollaras
| Name | Role | Notes |
|---|---|---|
Arthur Kollaras | Principal Engineer and Head of Manufacturing (KMP) | Chemical engineer and microbiologist; consultancy since 1 Oct 2021 at A$400 per hour |
Justin Reynolds | Chief Financial Officer (outsourced) | Partner, Pitcher Partners Sydney |
Maggie Niewidok | Company Secretary | Kardos Scanlan Corporate Lawyers |
Directors' Remuneration
| Name | Cash salary and fees | Long service leave | Superannuation | Bonus | Share-based payments | Total FY2026 | Total FY2025 |
|---|---|---|---|---|---|---|---|
James Graham | 660,707 | 32,103 | 30,000 | 0 | 216,450 | 939,260 | 1,292,191 |
John Prendergast | 368,730 | 0 | 0 | 0 | 202,722 | 571,452 | 758,025 |
Michele Dilizia | 361,109 | 17,152 | 30,000 | 0 | 115,440 | 523,701 | 454,447 |
Justin Ward | 280,000 | 7,661 | 33,600 | 0 | 72,150 | 393,411 | 366,290 |
Alan Dunton | 75,000 | 0 | 0 | 0 | 172,123 | 247,123 | 389,891 |
Alistair McKeough | 81,250 | 0 | 0 | 0 | 76,499 | 157,749 | 221,201 |
Arthur Kollaras | 525,920 | 10,205 | 63,110 | 0 | 43,104 | 642,339 | 745,804 |
Total KMP | 2,352,716 | 67,121 | 156,710 | 0 | 898,488 | 3,475,034 | 4,227,849 |
Directors' Remuneration by Feature
| Feature | Status |
|---|---|
Board size | 6 directors: 4 executive, 2 independent non-executive |
Independent majority | No. ASX Recommendation 2.4 not met. |
Chair independence / CEO separation | Chair is executive and not independent (Rec 2.5 not met). Chair and CEO roles are held by different people. |
Audit and Risk Management Committee | Chair: McKeough. Members: Dunton, Prendergast (executive). Met 4 times in FY26. Rec 4.1 not met because a member is executive. |
Nomination and Remuneration Committee | Chair: Dunton. Members: McKeough, Prendergast. Met 5 times. |
Board meetings FY26 | 5 (full attendance except McKeough, 4 of 5) |
Gender | Board: 5 men, 1 woman. Senior executives: 62% men, 38% women. |
Family relationships | CEO and CSO are reported to be the founder's grandson and daughter (Biotech Daily, 2019) |
Major Shareholders
| Holder | Shares | % |
|---|---|---|
Gavin William Brown | 40,195,981 | 13.15 |
Graham John Hamilton Melrose and Olga Mary Melrose (estate / joint holding) | 28,353,311 | 9.27 |
HSBC Custody Nominees (Australia) Ltd | 24,563,934 | 8.03 |
Buttonwood Nominees Pty Ltd | 10,765,714 | 3.52 |
Think Pink Pty Ltd (Rainbow A/C) | 9,075,000 | 2.97 |
Holders 6–10 | Not captured in this research | — |
James Graham (indirect) | 6,801,076 | 3,000,000 |
Michele Dilizia | 2,724,937 | 1,600,000 |
John Prendergast | 357,955 | 2,650,000 |
Justin Ward | 351,684 | 1,000,000 |
Alan Dunton (direct and indirect) | 146,288 | 2,250,000 |
Alistair McKeough (indirect) | 30,287 | 2,125,000 |
Arthur Kollaras | 107,514 | 700,000 |
Major Shareholders — G.J.H. and O.M. Melrose
| Holder | % |
|---|---|
G.J.H. and O.M. Melrose | 22.11 (stale notice; the register shows 9.27% in one account. Other related accounts may exist, and Mayne Report commentary cites about 13%.) |
Gavin William Brown | 13.68 |
FIL Limited (Fidelity International) | 8.57 |
Board & Management Changes
| Date | Event |
|---|---|
Nov 2024 AGM | Remuneration report second strike (74.41% For, below the 75% threshold). Spill resolution not passed. |
14 Nov 2025 | Death of founder and major shareholder Dr Melrose |
Nov 2025 AGM | Remuneration report receives 19.32% For (first strike of a new cycle). About 25.6% vote against the chair's re-election; three capital resolutions fail (Mayne Report). |
2 Sep 2026 GM | All six resolutions fail on poll despite strong proxy support (overall For: 19%–46%). Defeated items include piggyback options for SPP participants and for four directors, and ratification of the June 2026 placement. |
29 Sep 2026 | Section 249N shareholder notice proposing resolutions and nominating directors for the 2026 AGM. The requisitioning shareholder's identity and the resolutions' content were not captured in this research. |
6 Oct 2026 | Notice of 2026 AGM issued; meeting date not captured in this research |
Competitive Landscape
Competitors by Segment
| Segment | Competitor / product | Type | Positioning versus Recce |
|---|---|---|---|
DFI / ABSSSI (topical and systemic standard of care) | Generic antibiotics (amoxicillin-clavulanate, cephalexin, clindamycin, doxycycline, linezolid) | Incumbent standard of care | Cheap and entrenched. Recce's Australian Phase 3 compares directly against four physician-selected antibiotics. |
DFI / topical | Microbion Corp (pravibismane) | Private clinical-stage | Direct topical DFI competitor |
DFI / topical (historical) | Pexiganan (Dipexium / Locilex) | Failed Phase 3 | Shows the regulatory difficulty of topical DFI claims |
ABSSSI (systemic) | Basilea (Zevtera / ceftobiprole); Melinta (Baxdela, Orbactiv, Kimyrsa); Paratek (Nuzyra) | Commercial | Approved ABSSSI drugs with QIDP pathways |
cUTI / urosepsis (IV R327) | Shionogi (Fetroja / cefiderocol); Venatorx/Menarini (cefepime-taniborbactam); Iterum (Orlynvah / oral sulopenem); Spero/GSK (tebipenem HBr) | Commercial / late-stage | Strong Gram-negative competitors with deeper evidence |
HAP/VAP (inhaled R327) | Innoviva Specialty Therapeutics (Xacduro); Shionogi (cefiderocol); inhaled amikacin and tobramycin | Commercial | Systemic standard of care. Recce's angle is a nebulisable broad-spectrum agent. |
Novel-class AMR | BioVersys (SIX-listed; alpibectir, BV100); Bugworks; Armata Pharmaceuticals (phage) | Clinical-stage | Compete for AMR "new class" capital and pull incentives |
Burn wound infection | Silver sulfadiazine, mafenide, Soframycin (framycetin) | Generic standard of care | Recce's preclinical data claims superiority to Soframycin |
Peer Comparison FY2026
| Metric | Recce Pharmaceuticals | Iterum Therapeutics |
|---|---|---|
Stage | Phase 3 (pre-revenue) | Commercial (oral sulopenem approved US Oct 2024) |
Revenue, latest FY | Nil (FY2026) | — |
Net margin | n.m. (loss of A$14.96m) | — |
R&D intensity | n.m. (R&D cash A$11.66m in FY26) | — |



